Fewer Outpatient HF Med Adjustments on Dapagliflozin: DAPA-HF Fewer Outpatient HF Med Adjustments on Dapagliflozin: DAPA-HF
Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 27, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Dapagliflozin's Renal Protection Extends to'Fast Decline' of eGFR Dapagliflozin's Renal Protection Extends to'Fast Decline' of eGFR
Treatment of patients with type 2 diabetes with the SGLT2 inhibitor led to a significant drop in the occurrence of ' fast decline ' of renal function in DECLARE-TIMI 58, the drug ' s main cardiovascular outcome trial.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 25, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

DAPA-HF: Dapagliflozin Slows T2D Onset in Heart Failure Patients DAPA-HF: Dapagliflozin Slows T2D Onset in Heart Failure Patients
Dapagliflozin cut the relative incidence of new-onset type 2 diabetes by one third in patients with heart failure in the multicenter trial.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - June 16, 2020 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news

Dapagliflozin Benefits in HF Regardless of Diuretics: DAPA-HF Dapagliflozin Benefits in HF Regardless of Diuretics: DAPA-HF
The trial that turned an SGLT2 inhibitor into a heart failure drug also has clues to mechanisms behind the observed benefits. Contrary to early speculation, diuresis may be off the list.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 10, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

FDA OKs Farxiga for Heart Failure With Reduced Ejection Fraction
WEDNESDAY, May 6, 2020 -- The U.S. Food and Drug Administration has granted approval for Farxiga (dapagliflozin) oral tablets to treat adults with heart failure with reduced ejection fraction, the agency announced Tuesday. Farxiga is the first... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 6, 2020 Category: General Medicine Source Type: news

FDA Approves Diabetes Drug for Type of Heart Failure
The FDA today approved a new use for the diabetes drug, dapagliflozin (Farxiga), to reduce the risk of a hospital stay or death in people who have a type of heart failure. (Source: WebMD Health)
Source: WebMD Health - May 6, 2020 Category: Consumer Health News Source Type: news

FDA Approves Dapagliflozin (Farxiga) for Low-EF Heart Failure FDA Approves Dapagliflozin (Farxiga) for Low-EF Heart Failure
The widely anticipated approval makes dapagliflozin (Farxiga, AstraZeneca) the only drug in its class to be indicated for heart failure in the absence of diabetes.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 6, 2020 Category: Cardiology Tags: Cardiology News Alert Source Type: news

Farxiga Approved in the US for the Treatment of Heart Failure in Patients with Heart Failure with Reduced Ejection Fraction
6 May 2020 -- AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and hospitalisation for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 6, 2020 Category: Drugs & Pharmacology Source Type: news

New Study of Diabetes Drug for COVID-19 Raises Eyebrows
Some question the safety of AstraZeneca's just-launched DARE-19 study testing whether the type 2 diabetes drug dapagliflozin will reduce adverse outcomes of COVID-19. (Source: WebMD Health)
Source: WebMD Health - May 1, 2020 Category: Consumer Health News Source Type: news

New Study of Diabetes Drug for COVID-19 Raises Eyebrows New Study of Diabetes Drug for COVID-19 Raises Eyebrows
Some question the safety of AstraZeneca ' s just-launched DARE-19 study testing whether the type 2 diabetes drug dapagliflozin will reduce adverse outcomes of COVID-19.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - April 30, 2020 Category: Infectious Diseases Tags: Diabetes & Endocrinology News Source Type: news

Glenmark Pharma gets tentative USFDA nod for generic anti-diabetes tablets
Glenmark Pharmaceuticals on Wednesday said it has received tentative approval from the US health regulator for its generic Dapagliflozin and Saxagliptin anti-diabetes tablets. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 28, 2020 Category: Pharmaceuticals Source Type: news

Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious Covid-19 complications
Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in Covid-19 patients. The DARE-19 trial involves dapagliflozin, which is marketed in the United States as Farxiga and can reduce blood glucose levels in diabetes patients. The double-blind trial follows previous research indicating that the drug also may provide some protection to the heart and kidney for high-risk… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 25, 2020 Category: Biotechnology Authors: Brian Kaberline Source Type: news

Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious Covid-19 complications
Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in Covid-19 patients. The DARE-19 trial involves dapagliflozin, which is marketed in the United States as Farxiga and can reduce blood glucose levels in diabetes patients. The double-blind trial follows previous research indicating that the drug also may provide some protection to the heart and kidney for high-risk… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 25, 2020 Category: Pharmaceuticals Authors: Brian Kaberline Source Type: news

AstraZeneca and Saint Luke ’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients
AstraZeneca and Saint Luke's Mid America Heart Institute have initiated a randomised, global Phase III trial to assess the potential of Farxiga (dapagliflozin) as a treatment in patients hospitalised with COVID-19 who are at risk of developing serious complications, such as organ failure. (Source: World Pharma News)
Source: World Pharma News - April 23, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Diabetes Drug Slows Kidney Disease: DAPA-CKD Trial Stopped Early Diabetes Drug Slows Kidney Disease: DAPA-CKD Trial Stopped Early
AstraZeneca has announced that the phase 3 DAPA-CKD trial for dapagliflozin (Farxiga) in patients with chronic kidney disease has been halted early because of overwhelming efficacy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 31, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news